Infex Therapeutics has made significant enhancements to its senior leadership team, appointing Dr. Kerry Nield as Director of Clinical Programmes and promoting several existing staff members to key positions. Dr. Nield, who brings over 20 years of experience in pharmaceutical development, will oversee the clinical progression of Infex’s leading assets, RESP-X and MET-X. Professor Colm Leonard has been promoted to Executive Director and Chief Clinical Officer, and Dr. Victoria Savage has been elevated to Chief Scientific Officer. Also, Dr. Ian Cooper has been appointed as Chief Research Officer. The appointments are part of Infex’s strategy to advance its pipeline of anti-infective treatments, particularly those targeting antimicrobial resistance.

Biotechnology, Pharmaceuticals,United Kingdom